$23.60▾ 4.07%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-21.01MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+21.5%year over year
Decelerating
Still growing fast, but the pace has been easing.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Adaptive Biotechnologies Corporation is pre-profit. It is still burning cash while pre-profit. Still growing fast, but the pace has been easing.
Key numbers
Valuation
EPS (TTM)$-0.41
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-20.7%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$308.08M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Adaptive Biotechnologies Business Separation May Unlock Greater ValueAdaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses
Stock Market Today: S&P 500 Futures Fall, Dow Gains Amid US-Iran Agreement, SPCX Stock Surge—Dave And Buster's, Western Digital In Focus
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.